Braidwell »

Biogen Idec shares owned by Braidwell

Quarter-by-quarter ownership of Biogen Idec (BIIB) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Biogen Idec

Tip: Access up to 7 years of quarterly data

All positions including Biogen Idec held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biogen Idec by Braidwell

Quarter filed Position value Share count Share price at filing
2023-06-30 $35M 122k 284.85
2023-03-31 $61M 221k 278.03
2022-12-31 $70M 253k 276.92

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Biogen Idec

PRIMECAP Management Company
Vanguard Group
Wellington Management Company
Jpmorgan Chase & Co
Van Eck Associates Corp.
ClearBridge Advisors
Legal & General Group
T. Rowe Price Associates
Norges Bank Investment Management
Dimensional Fund Advisors
Bank of New York Mellon
Amundi
Deutsche Bank Aktiengesellschaft
Susquehanna International
Goldman Sachs Group

View all funds holding Biogen Idec